Sõda

MEEDIAVALVUR: algab „sõjalise erioperatsiooni“ teine etapp nimega „SÕDA“

Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

This drug was developed by Tracon Pharmaceuticals Inc.[2]

It is at Phase III trials for angiosarcoma.

References

Kommenteeri